Rhythm Pharma data show LT benefit of setmelanotide on hypothalamic obesity

Rhythm Pharmaceuticals announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society’s Annual Meeting at ObesityWeek…”We are excited to highlight the data showing meaningful, long-term benefits of setmelanotide in patients living with hyperphagia and severe obesity caused by rare MC4R pathway diseases at ObesityWeek,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “We believe the one-year BMI reduction of more than 25% in patients with hypothalamic obesity – where individuals trended towards normal body weight – is particularly encouraging as it shows continued improvement over our previously reported 16-week and six-month data. The hypothalamic obesity data affirm our confidence as we advance our pivotal, Phase 3 trial and work to bring setmelanotide to patients and families facing this challenging disease for which there are no approved, effective therapies.”